Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
HORA-PDE6b Gets FDA Rare Pediatric Disease Status
eyeDNA Therapeutics, a newly created subsidiary of Coave Therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) for HORA-PDE6b, the company’s novel gene therapy designed to treat inherited retinal dystrophy…
FDA Approves SB-007 for Stargardt Disease
The FDA has cleared an Investigational New Drug (IND) application for SB-007, an adeno-associated viral (AAV) vector gene therapy targeting the root genetic cause of Stargardt disease, according to a press release from SpliceBio. Addressing Stargardt Disease Across All ABCA4…
$2.7M NIH Grant to Study Retinal Connections in RP
A collaborative team from the University of Southern California (USC) and the University of Utah has been awarded a $2.7 million grant from the National Institutes of Health (NIH) to investigate how retinitis pigmentosa (RP) disrupts the visual wiring in…
Vabysmo Prefilled Syringe Approved in EU
The European Medicines Agency (EMA) has approved Roche’s Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). A Convenient Treatment…
Atsena Completes XLRS Gene Therapy Trial Dosing
Atsena Therapeutics has successfully completed dosing in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal delivery of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study represents an important step forward in developing…
Phenocell & Amarna Win Eurostars Grant
Phenocell SAS and Amarna Therapeutics have been awarded the prestigious Eurostars grant to advance their collaborative gene therapy platform targeting dry age-related macular degeneration (AMD). This partnership combines Phenocell’s innovative in vitro AMD disease model with Amarna’s proprietary gene delivery…
ACELYRIN Halts Izokibep Development | OBN
ACELYRIN has announced that the Phase 2b/3 clinical trial evaluating izokibep for non-infectious, non-anterior uveitis did not achieve its primary endpoint. The trial results did not demonstrate a statistically significant improvement in time to treatment failure versus placebo. Consequently, the…
Tenpoint and Visus Merge to Advance Eye Care
Tenpoint Therapeutics Ltd. and Visus Therapeutics Inc. have officially merged, combining their respective ophthalmic therapeutic assets to form a unified entity focused on addressing ocular conditions associated with aging, including presbyopia, cataracts, and geographic atrophy. Key Therapeutics in the Combined…
Fluoxetine Improves Visual Acuity in Adult Amblyopia
A groundbreaking study conducted by researchers from the Eye Research Center, Farabi Eye Hospital, and Tehran University of Medical Sciences has revealed that fluoxetine, a commonly used antidepressant, significantly improves visual acuity (VA) in adults with amblyopia. The study, led…
ViaLase, Moran Eye Center Collaborate on Glaucoma
ViaLase has announced a groundbreaking research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. This collaboration aims to accelerate glaucoma research by utilizing Moran’s state-of-the-art…